Effects of losartan on the mobilization of endothelial progenitor cells and improvement of endothelial function.
Through investigating the effect of the angiotensin receptor blocker (ARB) losartan on the number of endothelial progenitor cells (EPCs) and blood flow-mediated endothelium-dependent function (FMD) in the peripheral blood of patients with coronary heart disease (CHD), we found that FMD was improved and the number of circulating EPCs increased in the ARB treatment group (P <0.05). In addition, the increase in the number of EPCs was positively correlated with the improvement of FMD in the ARB treatment group (r = 0.52, P <0.01). These findings suggest that losartan may mobilize EPCs in the peripheral blood, improving endothelial function in CHD.